TSHA Stock Forecast & Price Target

Taysha Gene Therapies is viewed positively because TSHA-102 is generating unusually strong Rett syndrome data, with an 83% response rate at six months and a 100% response rate at 12 months in 12 initial patients, both far above the FDA’s 33% bar. The broad functional gains—310 total gains, including 31 developmental milestones, plus improvements in communication, motor function, sleep, and seizures—support the view that the therapy has clinically meaningful and durable benefit across age groups. Continued excellent safety, the likelihood of clearing the 1H27 interim hurdle, and a focused AAV-based CNS gene therapy platform targeting a disease with no approved disease-modifying therapy strengthen the company’s fundamental case.

Taysha Gene Therapies is a high-risk clinical-stage biotech with no approved products, so its value rests on unproven AAV programs that could still fail to show durable efficacy or a sufficiently clean safety profile. Although TSHA-102 has reported no treatment-related SAEs or DLTs across N=29 and NGN-401’s registrational dose shows N=35 with no treatment-related SAEs or DLTs, the discontinued higher dose triggered systemic hyperinflammatory syndrome/HLH-like immune toxicity, while late responses and uneven milestone gains suggest uncertain and heterogeneous benefit. The company also faces major regulatory, manufacturing, and competitive hurdles, and it is likely to need additional equity financing to fund development, creating meaningful dilution risk for shareholders.